About: BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.82 (+10.50%)
Status: Delisted — removed_from_provider. This asset is no longer trading; historical data is shown.
PHGENYSEBiomx Inc
Loading watchlist status…
Biomx Inc share price
PHGE price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
PHGE price performance
0%
5D
0%
1M
-56.31%
YTD
-90.11%
1Y
PHGE price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NYSE rank
N/ASector Rank
N/APHGE details
PHGE Market Signals